Quantbot Technologies LP Acquires New Position in Novo Nordisk A/S $NVO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Quantbot Technologies LP acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 63,017 shares of the company's stock, valued at approximately $4,376,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Copeland Capital Management LLC raised its position in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Park Square Financial Group LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Stone House Investment Management LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $30,000. Finally, Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $33,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NVO shares. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $83.75.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $53.81 on Tuesday. The stock has a market capitalization of $240.26 billion, a price-to-earnings ratio of 14.78, a PEG ratio of 1.80 and a beta of 0.63. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74. The firm's 50 day simple moving average is $64.52 and its 200-day simple moving average is $70.02. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 45.05%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.